oseltamivir phosphate
oseltamivir phosphate is listed in the FDA National Drug Code directory with 39 NDC codes, marketed under brand names including OSELTAMIVIR PHOSPHATE, oseltamivir phosphate, Oseltamivir Phosphate. Available dosage forms: for suspension, capsule, suspension, powder, for suspension, powder.
Drug details
- Generic Name
- oseltamivir phosphate
- Brand Names
- OSELTAMIVIR PHOSPHATE, oseltamivir phosphate, Oseltamivir Phosphate, Oseltamivir phosphate, Tamiflu
- Application Number
- ANDA209113
- Sponsor
- Zydus Pharmaceuticals USA Inc.
- NDC Codes
- 39
- Dosage Forms
- FOR SUSPENSION, CAPSULE, SUSPENSION, POWDER, FOR SUSPENSION, POWDER
- Routes
- ORAL
- Active Ingredients
- OSELTAMIVIR PHOSPHATE
Indications and Usage
1 INDICATIONS AND USAGE Oseltamivir Phosphate capsule is an influenza neuraminidase inhibitor (NAI) indicated for: Treatment of acute, uncomplicated influenza A and B in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours. ( 1.1 ) Prophylaxis of influenza A and B in patients 1 year and older. ( 1.2 ) Limitations of Use : Not a substitute for annual influenza vaccination. ( 1.3 ) Consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use. ( 1.3 ) Not recommended for patients with end-stage renal disease not undergoing dialysis. ( 1.3 ) 1.1 Treatment of Influenza Oseltamivir Phosphate capsule is indicated for the treatment of acute, uncomplicated illness due to influenza A and B infection in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours. 1.2 Prophylaxis of Influenza Oseltamivir Phosphate capsule is indicated for the prophylaxis of influenza A and B in patients 1 year and older. 1.3 Limitations of Use Oseltamivir Phosphate capsule is not a substitute for early influenza vaccination on an annual basis as recommended by the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices. Influenza viruses change over time. Emergence of resistance substitutions could decrease drug effectiveness. Other factors (for example, changes in viral virulence) might also diminish clinical benefit of antiviral drugs. Prescribers should consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use Oseltamivir Phosphate Capsule [see Microbiology (12.4)]. Oseltamivir Phosphate capsule is not recommended for patients with end-stage renal disease not undergoing dialysis [see Dosage and Administration (2.4) and Use in Specific Populations (8.6)].